NCT04661969

Brief Summary

Illicit subcutaneous injection of high-viscosity fluids for restoration and improvement of body contour is a growing trend all around the world. Many local and systemic complications have been described. Local complications include deformity at the site of injection, granulomas and several skin changes like erythema, induration, and plaques (well-circumscribed, elevated, superficial, solid lesion). The investigator designed a single-center, cross-sectional, retrospective, consecutive case series study and evaluated 49 surgeries performed in 35 patients with the history of foreign substances injection for cosmetic purposes and developed local complications. Investigators divided 4 groups accordingly to localization of foreign substances (FS). Group 1) FS disseminated to both lower extremities and buttocks; group 2) FS isolated to buttocks with moderate to severe skin changes, Group 3) FS isolated to lower legs with mild skin changes and superficial ulcerations and 4) FS isolated to lower legs with moderate to severe skin changes and/or ulceration. The investigators treated all patients surgically, which consisted of isolate ultrasonic liposuction for extraction of the material from the affected region (group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4). Statistical analysis was performed to find relations between type of surgery with complications, reactivation of symptoms, time for reactivation and a disease-free survival test (kaplan meier) was done.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
6.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2020

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2020

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

December 4, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 10, 2020

Completed
Last Updated

December 11, 2020

Status Verified

December 1, 2020

Enrollment Period

6.8 years

First QC Date

December 4, 2020

Last Update Submit

December 9, 2020

Conditions

Keywords

disease-freeautoimmune/inflammatory syndrome induced by adjuvants (ASIA)adjuvant disease

Outcome Measures

Primary Outcomes (1)

  • Complications

    Describe if patients have or not postoperative complications

    30 days

Secondary Outcomes (2)

  • Reactivation of symptoms

    9 to 76 months

  • Time for reactivation of symptoms

    9 to 76 months

Study Arms (4)

1

Foreign Substance disseminated to both lower extremities and buttocks

Procedure: Surgery

2

Foreign Substance isolated to buttocks with moderate to severe skin changes

Procedure: Surgery

3

Foreign substance isolated to lower legs with mild skin changes and superficial ulcerations

Procedure: Surgery

4

Foreign substance isolated to lower legs with moderate to severe skin changes and/or ulceration

Procedure: Surgery

Interventions

SurgeryPROCEDURE

(group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).

1234

Eligibility Criteria

Age24 Years - 64 Years
Sexfemale
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

patients previously injected with foreign substances (FS) such as polymers for cosmetic soft tissue augmentation and the diagnosis of ASIA presented with mild to severe skin changes and treated surgically from January 2014 to March 2020 all in a private practice setting (Hospital Angeles Pedregal, Mexico city, MEXICO) and treated all by plastic surgeon senior author (JLM)

You may qualify if:

  • History of injection of foreign substances for cosmetic purposes
  • Develop symptoms of Autoimmune syndrome induced by adjuvants
  • Mild to severe skin changes

You may not qualify if:

  • Refuse to participate in the analysis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Angeles Pedregal

Mexico City, Mexico City, 01330, Mexico

Location

MeSH Terms

Conditions

Granuloma, Foreign-BodyArthritis, Experimental

Interventions

Surgical Procedures, Operative

Condition Hierarchy (Ancestors)

GranulomaPathologic ProcessesPathological Conditions, Signs and SymptomsForeign-Body ReactionForeign BodiesWounds and InjuriesArthritisJoint DiseasesMusculoskeletal Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator, Plastic and reconstructive surgeon staff, MBA, FACS

Study Record Dates

First Submitted

December 4, 2020

First Posted

December 10, 2020

Study Start

January 1, 2014

Primary Completion

November 1, 2020

Study Completion

November 30, 2020

Last Updated

December 11, 2020

Record last verified: 2020-12

Locations